Chemotherapy after palliative resection of colorectal cancer. Yorkshire Gastrointestinal Tumour Group.
Patients with residual disease after palliative resection of colorectal cancer were randomly allocated to receive methyl CCNU and 5-Fluorouracil or followed conventionally. There was a short term improvement in overall survival at 2 years significant at the 5 per cent level but ultimately all patients died. Chemotherapy did not significantly delay progression or prolong survival in patients with local residual disease. Although patients with more disseminated disease had a poorer prognosis than those with more limited disease, survival at 18 months was significantly prolonged (P less than 0.02 greater than 0.01) by chemotherapy.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D012673:Semustine / Q000008:administration & dosage; D013997:Time Factors
D012673:Semustine; D005472:Fluorouracil